Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML by the SAL and OSHO Leukemia Study Groups Sonia Jaramillo Segura , Maxi Wass , Judith Schaffrath , Kathrin Rieger , Axel Nogai , Mathias Haenel , Regina Herbst , Friedrich Stoelzel , Christoph Roellig , Edgar Jost , Richard F. Schlenk , Richard Noppeney , Christian H. Brandts , Utz Krug , Katharina S. Goetze , Sebastian Buske , Axel Florschuetz , Joerg Schubert , Bernhard Opitz , Martin Mohren , Eva Esseling , Stephan von Witzendorff , Marion Subklewe , Martin Kaufmann , Norbert Frickhofen , Christian W. Scholz , Kerstin Schaefer-Eckart , Volker Kunzmann , Martin Schmidt-Hieber , Herbert G. Sayer , Andreas Rank , Philipp Hemmati , Frank Schueler , Simone Kowoll , Marina Scheller , Jorg Steighardt , Bayram Edemir , Lutz Peter Mueller , Irit Gliko-Kabir , Beatrice Ludwig-Kraus , Sabine Edemir , Ella Sorani , Mascha Binder , Abi Vainstein , Shaul Kadosh , Cora Gromann , Andreas Wienke , Claudia D. Baldus , Uwe Platzbecker , Hubert Serve , Martin Bornhaeuser , Christian Junghanss , Carsten Mueller-Tidow Blood（2022）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
